Brigham & Women's/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Eastern Virginia Medical School, School of Medicine, Norfolk, VA, USA.
J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 1:45-48. doi: 10.1111/jdv.17407.
Limited data exist on the use of immune checkpoint inhibitors (ICI) for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients (SOTR). We report a case of a SOTR who developed metastatic disease following multiple surgeries, three cycles of adjuvant radiotherapy, and minimization of immunosuppression. He was subsequently treated with pembrolizumab and achieved a complete response. However, the patient developed ICI-induced allograft rejection requiring therapy discontinuation. The allograft was salvaged following IVIg and steroids. The patient developed recurrent disease which failed rechallenge with pembrolizumab but achieved a partial response following cemiplimab administration. This case illustrates the potential to treat metastatic CSCC in a SOTR with anti-programmed death-1 therapy and preserve graft function despite allograft rejection.
关于免疫检查点抑制剂（ICI）在实体器官移植受者（SOTR）中治疗转移性皮肤鳞状细胞癌（CSCC）的应用，目前数据有限。我们报告了一例 SOTR 患者，他在多次手术后、三次辅助放疗和免疫抑制最小化后发生了转移性疾病。随后他接受了 pembrolizumab 治疗并获得了完全缓解。然而，患者发生了 ICI 诱导的移植物排斥反应，需要停止治疗。在 IVIg 和类固醇治疗后，移植物得以挽救。患者出现复发性疾病，再次接受 pembrolizumab 治疗失败，但接受 cemiplimab 治疗后获得部分缓解。该病例说明了在 SOTR 中使用抗程序性死亡-1 治疗治疗转移性 CSCC 并保留移植物功能的潜力，尽管发生了移植物排斥反应。
